The different biological effects of single, fractionated and continuous low dose rate irradiation on CL187 colorectal cancer cells

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Wang, Hao ^a   Li, Jinna ^a   Qu, Ang ^a   Liu, Jingjia ^a   Zhao, Yong ^b   Wang, Junjie ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b INSTITUTE OF ZOOLOGY   (China)

Author keywords

125I seeds; CL187 cell; DNA repair

Indexed keywords

IODINE 125; RADIOACTIVE IODINE;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER RADIOTHERAPY; CELL CYCLE PROGRESSION; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DNA REPAIR; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; WESTERN BLOTTING; X RAY; BRACHYTHERAPY; CELL CYCLE; COLORECTAL TUMOR; IMMUNOBLOTTING; PROCEDURES; RADIATION RESPONSE; RELATIVE BIOLOGIC EFFECTIVENESS; TUMOR CELL LINE;

APOPTOSIS; BRACHYTHERAPY; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMMUNOBLOTTING; IODINE RADIOISOTOPES; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 84881125106     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-196     Document Type: Article

References (31)

1. Nielsen MB, Laurberg S, Holm T. Current management of locally recurrent rectal cancer. Colorectal Dis 2011, 13:732-742. 10.1111/j.1463-1318.2009.02167.x, 20041928.
2. Wiig JN, Larsen SG, Dueland S, Flatmark K, Giercksky KE. Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome. Colorectal Dis 2011, 13:506-511. 10.1111/j.1463-1318.2010.02256.x, 20236148.
3. Lee JH, Kim DY, Kim SY, Park JW, Choi HS, et al. Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer. Radiat Oncol 2011, 6:51-58. 10.1186/1748-717X-6-51, 3118124, 21595980.
4. Vassil AD, Murphy ES, Reddy CA, Angermeier KW, Altman A, et al. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology 2010, 76:1251-1257. 10.1016/j.urology.2010.01.010, 20378156.
5. Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000, 46:221-230. 10.1016/S0360-3016(99)00351-X, 10656396.
6. Wang JJ, Jiang YL, Li JN, Tian SQ, Ran WQ, et al. Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res 2009, 28:188-193.
7. Jiang YL, Meng N, Wang JJ, Jiang P, Yuan HS, et al. CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers. Radiat Oncol 2010, 5:321-327.
8. Wang JJ, Yuan HS, Li JN, Jiang YL, Tian SQ, et al. CT-guided radioactive seed implantation for recurrent rectal carcinoma after multiple therapy. Med Oncol 2010, 27:421-429. 10.1007/s12032-009-9227-7, 19415534.
9. Wang JJ, Yuan HS, Li JN, Jiang WJ, Jiang YL, et al. Interstitial permanent implantation of 125I seeds as salvage therapy for re-recurrent rectal carcinoma. Int J Colorectal Dis 2009, 24:391-399. 10.1007/s00384-008-0628-4, 19084969.
10. Zhuang HQ, Wang JJ, Liao AY, Wang JD, Zhao Y. The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. J Exp Clin Cancer Res 2009, 28:334-345.
11. Wang JD, Wang JJ, Liao AY, Zhuang HQ, Zhao Y. The direct biologic effects of radioactive 125I seeds on pancreatic cancer cells PANC-1, at continuous low-dose rates. Cancer Biother Radiopharm 2009, 24:409-416. 10.1089/cbr.2008.0563, 19694575.
12. Liao AY, Wang JJ, Wang JD, Zhuang HQ, Zhao Y. Relative biological effectiveness and cell-killing efficacy of continuous low-dose-rate 125I seeds on prostate carcinoma cells in vitro. Integr Cancer Ther 2010, 9:59-65. 10.1177/1534735409357758, 20150222.
13. Aird EG, Folkard M, Mayes CR, Bownes PJ, Lawson JM, et al. A purpose built iodine-125 plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol 2001, 74:56-61.
14. Liu X, Ma B, Malik AB, Tang H, Yang T, Sun B, et al. Bidirectional regulation of neutrophilmigration by mitogen-activated protein kinases. Nat Immunol 2012, 457:464.
15. Salles B, Calsou P, Frit P, Muller C. The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol Biol (Paris) 2006, 54:185-193.
16. Burdak-Rothkamm S, Prise KM. New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells. Eur J Pharmacol 2009, 625:151-155. 10.1016/j.ejphar.2009.09.068, 2855957, 19835868.
17. Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One 2013, 8:e60408. 10.1371/journal.pone.0060408, 3614551, 23565244.
18. Ngwa W, Korideck H, Kassis AI, Kumar R, Sridhar S, et al. In vitro radiosensitization by gold nanoparticles during continuous low-dose-rate gamma irradiation with I-125 brachytherapy seeds. Nanomedicine 2013, 9:25-27. 10.1016/j.nano.2012.09.001, 23041410.
19. Marchese MJ, Hall EJ, Hilaris BS. Encapsulated iodine-125 in radiation oncology. I. Study of the relative biological effectiveness (RBE) using low dose rate irradiation of mammalian cell cultures. Am J Clin Oncol 1984, 7:607-611. 10.1097/00000421-198412000-00005, 6528858.
20. Wuu CS, Kliauga P, Zaider M, Amols HI. Microdosimetric evaluation of relative biological effectiveness for 103Pd, 125I, 241Am, and 192Ir brachytherapy sources. Int J Radiat Oncol Biol Phys 1996, 36:689-697. 10.1016/S0360-3016(96)00374-4, 8948355.
21. Lehnert S, Reniers B, Verhaegen F. Relative biologic effectiveness in terms of tumor response of 125I implants compared with 60Co gamma rays. Int J Radiat Oncol Biol Phys 2005, 63:224-229. 10.1016/j.ijrobp.2005.05.009, 16111593.
22. Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, et al. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm 2001, 16:213-225. 10.1089/10849780152389401, 11471486.
23. Nakajima T. Signaling cascades in radiation-induced apoptosis: roles of protein kinase C in the apoptosis regulation. Med Sci Monit 2006, 12:220-224.
24. Mirzaie-Joniani H, Eriksson D, Sheikholvaezin A, Johansson A, Lofroth PO, et al. Apoptosis induced by low-dose-rate radiation. Cancer 2002, 94:1210-1214. 10.1002/cncr.10287, 11877747.
25. Vavrova J, Rezacova M, Vokurkova D, Psutka J. Cell cycle alteration, apoptosis and response of leukemic cell lines to gamma radiation with high- and low-dose rate. Physiol Res 2004, 53:335-342.
26. Vamvakas S, Vock EH, Lutz WK. On the role of DNA double-strand breaks in toxicity and carcinogenesis. Crit Rev Toxicol 1997, 27:155-174. 10.3109/10408449709021617, 9099517.
27. DiBiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJ, et al. DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res 2000, 60:1245-1253.
28. Muller C, Christodoulopoulos G, Salles B, Panasci L. DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood 1998, 92:2213-2219.
29. Korabiowska M, Cordon-Cardo C, Schinagl M, Karaus M, Stachura J, et al. Loss of Ku70/Ku80 expression occurs more frequently in hereditary than in sporadic colorectal tumors. Hum Pathol 2006, 37:448-452. 10.1016/j.humpath.2005.11.016, 16564919.
30. Mazzarelli P, Parrella P, Seripa D, Signori E, Perrone G, et al. DNA end binding activity and Ku70/80 heterodimer expression in human colorectal tumor. World J Gastroenterol 2005, 11:6694-6700.
31. Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, et al. Prognostic significance of Ku70 protein expression in patients with advanced colorectal cancer. Hepatogastroenterology 2005, 52:995-998.